IVF / ICSI / IUI for Male Factor
Assisted Reproductive Technologies from the male side
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Established clinical procedures (regulated as medical practice; ICSI introduced 1992)
Reference only. Not medical advice.
What can go wrong
ICSI carries a small but real increase in imprinting disorders (Beckwith-Wiedemann, Angelman) and may transmit the male infertility phenotype to sons (Y-microdeletions). IVF/ICSI involve ovarian stimulation risks borne by the female partner (OHSS, multiple gestation). The central controversy is iatrogenic: ICSI is applied to couples with normal sperm where it offers no benefit over conventional IVF and may slightly lower live-birth rates while adding cost.
This is something to take to a clinician. The Atlas can tell you what is known about ivf / icsi / iui for male factor in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Intrauterine insemination (IUI), in-vitro fertilization (IVF), and intracytoplasmic sperm injection (ICSI) form an escalating ladder of assisted reproduction. For male factor, IUI concentrates washed sperm and deposits it in the uterus; conventional IVF mixes sperm and eggs in a dish; ICSI injects a single sperm directly into each egg, bypassing nearly every barrier sperm normally must cross. ICSI was developed for severe male factor but has expanded far beyond its evidence base.
Three escalating procedures, one frequently-overused workhorse.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
IUI bypasses cervical mucus and shortens the distance sperm travel, requiring adequate post-wash motile count. Conventional IVF requires sperm to bind and penetrate the egg unaided in vitro. ICSI bypasses sperm capacitation, zona binding, acrosome reaction and oolemma fusion entirely - an embryologist selects one sperm under high magnification and injects it, making fertilization possible with single viable sperm, including immotile or surgically extracted sperm.
What people get wrong
Often saidICSI gives every couple a better chance of a baby
ActuallyICSI was designed for severe male factor. For couples with normal semen parameters, large registry data show no live-birth advantage over conventional IVF - and it adds cost and a theoretical bypass of natural sperm selection.
Often saidIUI is worth many tries before moving on
ActuallyWith significantly impaired sperm, IUI success collapses; guidelines favor moving to IVF/ICSI rather than repeating low-yield IUI cycles.
Who profits, and who pushes back
ASRM Practice Committee
Its committee opinion concludes that routine ICSI for non-male-factor indications - including advanced maternal age, low oocyte yield, and unexplained infertility - does not improve live birth rates and is not supported by the evidence outside specific male-factor or prior-fertilization-failure scenarios.
SART / registry-outcome researchers
Find that non-indicated ICSI does not raise fertilization or cumulative live birth rates compared with conventional IVF, meaning many couples are treated with the more expensive technique without measurable benefit.
Investigators of randomized IVF-vs-ICSI trials
Report that, in couples without severe male factor, ICSI does not outperform conventional IVF on key outcomes, reinforcing that its use should be reserved for clear indications.
How we got here
IUI descends from centuries of insemination attempts; modern washed-sperm IUI matured in the late 20th century. IVF produced Louise Brown in 1978 (Steptoe and Edwards; Edwards won the 2010 Nobel). ICSI arrived in 1992 from Gianpiero Palermo's lab in Brussels - reportedly after an accidental oolemma penetration - and transformed severe male-factor treatment within a few years.
- 1978First IVF birth (Louise Brown)
- 1992First ICSI pregnancies reported
- 2010Robert Edwards awarded Nobel Prize
- 2015-2020ASRM/SART caution against routine ICSI overuse
Set against the alternatives
By indication, success diverges sharply. For severe male factor, ICSI fertilization rates (~70-80% of injected eggs) vastly exceed conventional IVF. For normal sperm, conventional IVF matches or beats ICSI on live birth. IUI cycle live-birth rates are modest (~10-15% per cycle in good prognosis) and fall steeply with declining sperm quality.
| Method | Best indication | Invasiveness | Relative cost / cycle |
|---|---|---|---|
| IUI | Mild male factor, unexplained | Low | Lowest (hundreds-low thousands) |
| Conventional IVF | Tubal, moderate male factor | Moderate-high | High (mid five figures) |
| ICSI | Severe male factor, prior fert. failure | High (adds micromanipulation) | Highest (IVF plus ICSI add-on) |
| ICSI for non-male factor | Not evidence-supported | High | Adds cost without proven benefit |
What we do not know
- Does ICSI's bypass of natural sperm selection have long-term offspring health consequences?
- Can sperm-selection methods (microfluidics, hyaluronan binding) improve on random ICSI selection?
- Why does ICSI use keep rising against guideline advice - reimbursement, risk aversion, or lab logistics?
What could change
Evidence-based de-escalationGuideline pressure to reserve ICSI for true indications and reduce overuseAI / automated sperm selectionAlgorithm-assisted selection of sperm for injectionMicrofluidic sperm sortingSelecting higher-quality, lower-DNA-damage sperm before ICSISperm DNA and epigenetic markersRefining which couples genuinely benefit from ICSILong-term offspring follow-upContinued study of health outcomes in ICSI-conceived children
At a glance
- ICSI first birth
- 1992 (Palermo, Brussels)
- IUI sperm threshold
- commonly >5-10 million motile post-wash
- US ICSI use
- ~65-70% of all IVF cycles despite male factor in a minority
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about IVF / ICSI / IUI for Male Factor. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Palermo et al., Lancet - first ICSI pregnancies1992
Established direct sperm injection as viable for severe male factor
Practice Committee ASRM/SART on ICSI use2020
Concluded routine ICSI for non-male-factor and unexplained infertility is not supported by evidence
Boulet et al., JAMA - US ICSI trends2015
ICSI use rose from 36% to 76% of cycles 1996-2012 with no improvement in outcomes for non-male-factor cases